Skip to main content

DArecca James's Form 4 filing

TherapeuticsMD, Inc. (TXMD) · filed Aug 12, 2021

Accession no.
0001387131-21-008437
Filed
Aug 12, 2021
Trade date
Aug 10-12, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $81.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
DArecca JamesCIK 0001583903Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 10, 2021Common StockMOption exerciseAcquired+217,167–F1–217,167Direct
Aug 12, 2021Common StockSSaleDisposed−93,337$0.87F3−$81,203.19123,830Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 10, 2021Common StockMOption exerciseDisposed−217,167$0.00$0434,333Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $0.87 to $0.88. The price reported in Column 4 reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)